Castration-sensitive
A032302
Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
